Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting

Table 2 Monthly headache days and hours at baseline (T0) and after 6 (T6), 12 (T12), and 18 months (T18)

		T0	T6	T12	T18
Monthly days with headache	Mean ± SD	25.9 ± 5.3	11.5 ± 8.8	9.6 ± 6.8	6.3 ± 5.7
Monthly days with headache	Median (q1–q3)	30 (20–30)	9 (4–18)	8 (5–14)	5 (2–8)
	Range 95% CI n	15–30 23.0–29.1 47	0–30 9.6–13.8 47	0–30 8.0–11.7 47	0–30 5.0–8.0 47
Monthly hours with headache	Mean ± SD	547.7 ± 183.4	173.4 ± 195.3	90.4 ± 93.9	53.2 ± 79.2
Monthly hours with headache	Median (q1–q3)	600 (400–700)	100 (30–250)	60 (20–120)	25 (12–50)
	Range 95% CI n	112–720 478.4–627.0 47	0–700 136.3–220.5 47	0–400 64.8–126.1 47	0–350 34.5–82.2 47
p values from HGLM and pairwise comparisons
Outcome	p for overall difference	T6 vs. T0	T12 vs. T6	T18 vs. T12	p for trend
Monthly days with headache	<0.001	<0.001	0.072	0.001	<0.001
Monthly hours with headache	<0.001	<0.001	<0.001	0.013	<0.001